Concepedia

Ingrid Almeciga-Pinto

IA

Statistics

Publications

3

Citations

189

H-Index

3

Active since

2015

Affiliations

Acetylon Pharmaceuticals (United States)(Current)

Massachusetts General Hospital

Harvard University

Ingrid Almeciga-Pinto is an author at Acetylon Pharmaceuticals (United States) specializing in cancer therapeutics, cancer research, and medicine.

Top concepts

Publications per year

2015–2017

3

Publications

3

Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models

Pengyu Huang, Ingrid Almeciga-Pinto, Matthew Jarpe et al. · Oncotarget · 2016 · 121 citations · Full text

, , +16

Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor

Brian J. North, Ingrid Almeciga-Pinto, David Tamang et al. · PLoS ONE · 2017 · 47 citations · Full text

, , +18

ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD®) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study)

Rubén Niesvizky, Paul G. Richardson, Nashat Gabrail et al. · Blood · 2015 · 21 citations

1–3 of 3